All In Biotech

NDA 202763 · Ani Pharms

Testosterone

Testosterone · Transdermal

Discontinued

Last checked: Nov 20, 2026Latest source record: Oct 25, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Feb 14, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

173 Phase 3, 64 recruiting

FAERS reports

19,071

10,928 serious, 779 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TESTOSTERONE · TESTOSTERONE 25MG/2.5GM PACKET · GEL, TRANSDERMAL · Discontinued
  • TESTOSTERONE · TESTOSTERONE 50MG/5GM PACKET · GEL, TRANSDERMAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,467
  • off label use1,232
  • fatigue1,182
  • nausea858
  • headache776
  • pain776
  • diarrhoea628
  • anxiety611
  • asthenia598
  • arthralgia595
  • dizziness593
  • dyspnoea549

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004169
2005126
2006139
2007156
2008188
2009248
2010307
2011334
2012875
2013367
2014556
20151,102
20161,059
2017977
20181,138
20191,225
20201,198
20211,206
20221,419
20231,550
20241,640
20251,721
20261,371

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Testosterone (Testosterone)

2024 spending

$93.4M

Beneficiaries

132,638

556,670 claims

Per beneficiary

$704

$1.21 per unit

View as table
YearSpending
2020$137,780,191
2021$124,155,588
2022$116,014,874
2023$116,855,572
2024$93,434,856

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,506 on PubMed

Sponsor: Ani Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.